Celcuity LLC (CELC) - Total Liabilities
Based on the latest financial reports, Celcuity LLC (CELC) has total liabilities worth $359.04 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. For the complete balance sheet picture, see how large is Celcuity LLC's balance sheet.
Celcuity LLC - Total Liabilities Trend (2015–2024)
This chart illustrates how Celcuity LLC's total liabilities have evolved over time, based on quarterly financial data. Explore CELC long-term investment intensity to see how much of total assets are deployed in long-term investments.
Celcuity LLC Competitors by Total Liabilities
The table below lists competitors of Celcuity LLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cochin Shipyard Limited
NSE:COCHINSHIP
|
India | Rs86.58 Billion |
|
International Bancshares Corporation
NASDAQ:IBOC
|
USA | $13.65 Billion |
|
Suven Pharmaceuticals Limited
NSE:SUVENPHAR
|
India | Rs11.91 Billion |
|
Novanta Inc
F:1GSN
|
Germany | €704.34 Million |
|
Union Bank of Taiwan Pref
TW:2838A
|
Taiwan | NT$970.36 Billion |
|
BGC Group Inc.
NASDAQ:BGC
|
USA | $4.59 Billion |
|
NorthWestern Corporation
NASDAQ:NWE
|
USA | $5.81 Billion |
|
LivaNova PLC
NASDAQ:LIVN
|
USA | $1.32 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Celcuity LLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. Check CELC asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.75 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Celcuity LLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Celcuity LLC (2015–2024)
The table below shows the annual total liabilities of Celcuity LLC from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $129.50 Million | +151.71% |
| 2023-12-31 | $51.45 Million | +22.72% |
| 2022-12-31 | $41.93 Million | +143.81% |
| 2021-12-31 | $17.20 Million | +1270.76% |
| 2020-12-31 | $1.25 Million | +27.59% |
| 2019-12-31 | $983.23K | +44.12% |
| 2018-12-31 | $682.21K | +18.02% |
| 2017-12-31 | $578.05K | +29.79% |
| 2016-12-31 | $445.36K | +57.04% |
| 2015-12-31 | $283.60K | -- |
About Celcuity LLC
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2… Read more